Key statistics
On Friday, BEIGENE LTD (BGNEN:MEX) closed at 2,858.16, 0.00% below its 52-week high of 2,858.16, set on Jan 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 2,858.16 |
Low | 2,858.16 |
Bid | -- |
Offer | -- |
Previous close | 2,858.16 |
Average volume | -- |
---|---|
Shares outstanding | 106.19m |
Free float | 102.94m |
P/E (TTM) | -- |
Market cap | 27.29bn USD |
EPS (TTM) | -5.08 USD |
Data delayed at least 20 minutes, as of Jan 19 2024 11:30 GMT.
More ▼
Press releases
- BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
- Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
- BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
- BeiGene Announces Updates to Commercial Leadership Team
- BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
- BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
- BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
- BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
- BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
More ▼